Marinus Pharmaceuticals Reveals Phase 3 TrustTSC Trial Findings
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), known for its commitment to developing breakthrough therapies for seizure disorders, has recently provided an update regarding its Phase 3 TrustTSC trial. This study evaluated the efficacy of oral ganaxolone in treating seizures associated with tuberous sclerosis complex (TSC) in both children and adults. Despite showing a trend toward reduced seizure frequency in participants treated with ganaxolone, the trial did not meet the primary endpoint of statistically significant reduction in TSC-related seizure frequency over a 28-day period.
Trial Overview and Key Findings
The TrustTSC trial was a global endeavor comprising 129 participants, conducted in a double-blind, placebo-controlled format. This design is pivotal as it emphasizes scientific rigor and unbiased results. Key findings from the trial illustrated that while participants receiving ganaxolone experienced a median seizure reduction of 19.7%, the placebo group noted a 10.2% reduction, resulting in a p-value of 0.09—a figure that falls short of the significance threshold required for regulatory considerations.
Adverse Events and Safety Profile
Throughout the study, ganaxolone exhibited a safety profile consistent with earlier trials. The most common adverse effect reported was somnolence, observed in 28.1% of the ganaxolone group compared to 16.9% in the placebo cohort. This highlights the importance of careful monitoring and assessment of adverse events in future developments.
Strategic Shifts Following Trial Results
In response to the outcomes of the TrustTSC trial, Marinus Pharmaceuticals has made the decision to discontinue further development of ganaxolone for TSC-related indications. This move is part of a broader strategy to optimize resources and cut costs, ultimately leading to a workforce reduction. Simultaneously, the company is embarking on a review of strategic alternatives designed to enhance shareholder value.
Engagement of Financial Advisors
Marinus has enlisted the services of Barclays as a strategic advisor to assist in exploring various alternatives that could benefit stockholders. The company acknowledges the uncertainty inherent in this exploration process, where numerous outcomes are possible.
Continued Commitment to ZTALMY
Despite these challenges, Marinus remains committed to the commercialization of ZTALMY® (ganaxolone) oral suspension, which is FDA-approved for the treatment of seizures associated with CDKL5 deficiency disorder. Over 200 patients are currently benefiting from this treatment. The company plans to maintain its support and investments into the growth of ZTALMY, underscoring its importance in the company's portfolio.
Understanding Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by the development of benign tumors in various organs and is commonly associated with severe neurological issues, including epilepsy. The condition can lead to significant challenges for individuals affected, often leading to various treatment protocols to manage the neurological symptoms, especially seizures.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals is a pioneering commercial-stage pharmaceutical company focused on creating transformative solutions for those suffering from seizure disorders. With the introduction of ZTALMY® in 2022, Marinus continues to make strides within the pharmaceutical landscape, contributing to the well-being of patients with challenging seizure disorders.
Frequently Asked Questions
What were the primary results of the Phase 3 TrustTSC trial?
The trial did not meet its primary endpoint, showing a 19.7% reduction in seizures with ganaxolone, compared to 10.2% for placebo, with a p-value of 0.09.
What is ganaxolone?
Ganaxolone is a neuroactive steroid and GABAA receptor modulator used in certain therapeutic contexts, including treatment for seizure disorders.
What changes are Marinus Pharmaceuticals making after the trial?
Marinus is discontinuing further clinical development of ganaxolone for TSC, reducing its workforce, and exploring strategic alternatives to enhance shareholder value.
What is the future for ZTALMY?
Marinus will continue to promote ZTALMY and support its growth, as it is FDA-approved for treating seizures related to CDKL5 deficiency disorder.
How does Tuberous Sclerosis Complex affect patients?
TSC can lead to various health complications, including the development of benign tumors and severe neurological manifestations such as refractory seizures.
